Investor Information

Nine Plus Two is developing proprietary platforms for high-throughput screening with zebrafish. This platform will allow unprecedented development of model systems for neural defects and other mutation systems that will enable large scale drug development and gene therapy studies using a vertebrate.

Investors interested in more information should contact, David Mann, President.